Venerol® – a unique and
Extensive research has laid the foundation to the unique invention Venerol®. Venerol® is a patented drug delivery technology and forms the basis of our first product.
The drug delivery technology Venerol®, has a great potential to distribute and stabilize various substances, when combined with the technology, that would have otherwise been degraded or unsuitable as a topical treatment. Having this innovative application, Pharmiva has a good platform to expand the product portfolio to additional treatment areas.
An antibiotic-free vaginal mousse for the treatment of bacterial vaginosis
over-the-counter, vaginal mousse for the treatment of
bacterial vaginosis. Vernivia®, derived as the result from
extensive research on vaginal health treatments, and based
on the patented drug delivery technology Venerol®.
Vernivia® – an over-the-counter, clinically tested vaginal mousse
Vernivia® is one of the first clinically proven, over-the counter and antibiotic free treatment for bacterial vaginosis currently available on the market. The vaginal mousse restores a healthy vaginal pH-balance and strengthens the vaginas own defenses against harmful bacteria by reinforcing the increase of good lactic acid bacteria (lacrobacilli), natural producers of lactic acid and hydrogen peroxide.
Pharmiva’s unique delivery technology provides treatment to the infected areas by enabling the product to reach and cover all mucosal folds inside the vagina.
Vernivia® is free from antibiotics, perfumes, parabens and hormones.
The clinical study which paved the way for Pharmiva’s first product, Vernivia®, was conducted on women diagnosed with bacterial vaginosis. Findings showed that after treatment with Vernivia®, the number of lactic acid bacteria increased, thus restoring the natural bacterial flora in the vagina. Vernivia® demonstrated a curative effect comparable to that of local antibiotic treatments, and a superior symptom control compared to antibiotics.1
The clinical findings confirm that Vernivia® is an effective over-the-counter treatment and a good alternative to antibiotics for the treatment of bacterial vaginosis.
The antimicrobial effect of Vernivia® has been confirmed by cell based in vitro studies. The findings indicate that low doses of Vernivia® (1:100 dilution) inhibits the growth of Neisseria gonorrhoeae (gonorrhea) and Gardnerella vaginalis (bacterial vaginosis.
Ongoing clinical studies
Clinical study bacterial vaginosis (BV)
Based on findings from the proof-of-concept study, Pharmiva initiated a post-market clinical follow-up (PCMF) study using a multi-dosage approach.
The study is randomized, double-blinded and placebo-controlled, with the intention of including 96 patients diagnosed with bacterial vaginosis. Patients’ symptoms and curation are monitored throughout the trial, which includes a follow up after finalizing the treatment.
The aim of the study is to investigate the effect of the treatment on women, 18 years of age and older, with a verified diagnosis of bacterial vaginosis.
Patient recruitment will start in January 2021, and the study is expected to be completed by the end of 2022, due to delays caused by the covid-19 pandemic.
Vernivia® user study
Pharmiva conducted a clinical user study which ran over the first half of 2021, in preparations for the upcoming commercial launch.
The study was carried out in collaboration with gynecology clinics and other relevant healthcare centers. For inclusion, patients were required to experience clinical symptoms of bacterial vaginosis.
The aim of the study was to evaluate user perspectives and to set the prerequisites for a commercial launch, based on education and product knowledge among both healthcare providers and patients. The study was designed and implemented as a tool during contact with distributors and partners, including pharmacy chains
Upcoming clinical trials
- K. Breding et al. GWHR,1, 1-10, 2018.